cvot tirzepatide Long-awaited SURPASS-CVOT: Cardiovascular Outcomes with vs Dulaglutide in NEJM: #tirzepatide noninferior to #dulaglutide for 3-point MACE in T2D with ASCVD, with greater improvements in weight, A1c, BP, triglycerides, and kidney function What do topline data from
Pay in 4 interest-free payments of $5.51 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9














:max_bytes(150000):strip_icc()/Health-GettyImages-2242656837-7ba7eeb1b08d43c681f154b32e6dc07c.jpg)










